2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2024-03-08 |
|
2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2024-03-08 ±³À°ÁÖÁ¦ : 2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) ÁÖÃÖ±â°ü : ´ëÇÑ°©»ó¼±ÇÐȸ À̸ÞÀÏ : office@thyroid.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, À̺ñÀÎÈÄ°ú, ¿µ»óÀÇÇаú, º´¸®°ú, ÇÙÀÇÇаú Âü¼®¿¹»óÀÎ : 350¸í Áö¿ª : ´ëÀü±¤¿ª½Ã ¼¼ºÎ¼ö°·á : 120,000¿ø ºñ°í " 1. Àü¹®ÀÇ/ÀϹÝÀÇ 1) Æò»ýȸ¿ø ¹× Á¤È¸¿ø(¿¬È¸ºñ ³³ºÎÀÚ) »çÀüµî·Ï 90,000¿ø, ÇöÀåµî·Ï 110,000¿ø, 2) ºñȸ¿ø »çÀüµî·Ï 100,000¿ø, ÇöÀåµî·Ï 120,000¿ø 2. Àü°øÀÇ/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/°£È£»ç/±âÃÊÀÇÇÐÀÚ 1) Æò»ýȸ¿ø ¹× Á¤È¸¿ø(¿¬È¸ºñ ³³ºÎÀÚ) »çÀüµî·Ï 50,000¿ø, ÇöÀåµî·Ï 70,000¿ø, 2) ºñȸ¿ø »çÀüµî·Ï 70,000¿ø, ÇöÀåµî·Ï 90,000¿ø 3. ¸¸65¼¼ ÀÌ»óÀÎ Æò»ýȸ¿ø, Çкλý ¹× ÀÇÀü¿ø Çлý : ¹«·á"
±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 13:00~13:20 Oncocytic tumor: Radiologic perspective ÇѼö¿¬(¼º±Õ°üÀÇ´ë ¿µ»óÀÇÇаú) ±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 13:20~13:40 Pathologic perspectives ½ÅÇüÂù(°è¸íÀÇ´ë º´¸®°ú) ±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 13:40~14:00 Clinical perspectives ±è¼ö¿µ(¾ÆÁÖÀÇ´ë ¿Ü°ú) Åä·Ð 03¿ù 08ÀÏ 201È£ 14:00~14:10 Discussion () ±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 14:10~14:30 Appropriate RAI treatment strategies for low-intermediate risk DTC ±èÈñ°æ(Àü³²ÀÇ´ë ³»°ú) ±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 14:30~14:50 Risk and benefits of high-dose RAI treatment for advanced DTC ¿À¼Ò¿ø(¼¿ïÀÇ´ë ÇÙÀÇÇаú) ±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 14:50~15:10 Defining RAI refractory thyroid cancer & when to start TKI treatment ±è¿ø±¸(¿ï»êÀÇ´ë ³»°ú) Åä·Ð 03¿ù 08ÀÏ 201È£ 15:10~15:20 Discussion () ÈÞ½Ä 03¿ù 08ÀÏ 201È£ 15:20~15:40 Coffee Break () ±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 15:40~16:20 ±×·¹À̺꽺º´ÀÇ Ä¡·á½Ã Ç×°©»ó¼±Á¦ »ç¿ë ¼Û¿µ±â(¶¯Å¥¼¿ïÀÇ¿ø ³»°ú) ±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 16:20~16:40 Early Rehabilitation after Thyroid Surgery ¹ÚÁø¿µ(¿¬¼¼ÀÇ´ë ÀçÈ°ÀÇÇаú) ±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 16:40~17:00 Psychosocial Support for Thyroid Cancer Survivors Á¶ÁÖÈñ(¼º±Õ°ü´ëÇб³ »ï¼ºÀ¶ÇÕÀÇ°úÇпø) ±³À°½Ã°£ 03¿ù 08ÀÏ 201È£ 17:00~17:20 Nutrition Care after Thyroid Cancer Surgery °ÀºÈñ(¼¿ï¾Æ»êº´¿ø ¿µ¾çÆÀ) Åä·Ð 03¿ù 08ÀÏ 201È£ 17:20~17:30 Discussion () ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 13:00~13:10 [±¸¿¬¹ßÇ¥] Long-Term Clinical Outcomes and Prognostic Factors of Medullary Thyroid Carcinoma Over 30 Years "¿À¹®¿µ (¼¿ïƯº°½Ãº¸¶ó¸Åº´¿ø ¿Ü°ú)" ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 13:10~13:20 [±¸¿¬¹ßÇ¥] A Protein Tumor Marker in Fine Needle Aspiration Washout Fluid: Insights from a Dual Cohort Analysis of Thyroid Cancer Patients "ÀÌÁ¤¹Î (°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ³»°ú)" ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 13:20~13:30 [±¸¿¬¹ßÇ¥] Endotrophin promotes tumor growth by supporting immune-suppressive hypoxic microenvironments in anaplastic thyroid cancer "±èÀ¯Çü (¼¿ï´ëÇб³º´¿ø ³»ºÐºñ³»°ú)" ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 13:30~13:40 [±¸¿¬¹ßÇ¥] Performance enhancement of a heart rate-based thyrotoxicosis prediction machine learning-assisted system through reference to multiple TFT Results "½Å±Ôº¸ (ÁÖ½Äȸ»ç ŸÀ̷νºÄÚÇÁ)" ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 13:40~13:50 [±¸¿¬¹ßÇ¥] In Graves' disease surgery, goiter size may be more important than the patient's preoperative euthyroid status "À¯ÁöÇö (»ï¼º¼¿ïº´¿ø ³»ºÐºñ´ë»ç³»°ú)" ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 13:50~14:00 [±¸¿¬¹ßÇ¥] Highly Targeted TERT Mutation Detection in Thyroid Cancer Through Digital Droplet PCR "ÀÌÁ¤¹Î (°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ³»°ú)" ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 14:10~14:20 [±¸¿¬¹ßÇ¥] Selenium Efficacy in Mild-to-Moderate Graves¡¯ Ophthalmopathy within Selenium-Sufficient Regions (SeGOSS Trial): A Phase III, Multicenter, Open-Label, Randomized, Controlled Intervention Study "ÀåÁø¼± (¼¿ï´ëÇб³º´¿ø ³»ºÐºñ³»°ú)" ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 14:20~14:30 [±¸¿¬¹ßÇ¥] Prognosis of patients with brain metastases of differentiated thyroid carcinoma "±èä¾Æ (¼¿ï¾Æ»êº´¿ø ³»ºÐºñ³»°ú)" ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 14:30~14:40 [±¸¿¬¹ßÇ¥] Utilizing IgG4 Immunohistochemistry for Risk Stratification in Patients with Papillary Thyroid Carcinoma Associated with Hashimoto Thyroiditis "Á¤Âù±Ç (¼¿ï¼º¸ðº´¿ø º´¸®°ú)" ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 14:40~14:50 [±¸¿¬¹ßÇ¥] Validation of Glandy CAS Software in the Assessment of Thyroid Eye Disease Activity: A Confirmatory Clinical Trial "±èÁ¾Âù (ÁÖ½Äȸ»ç ŸÀ̷νºÄÚÇÁ)" ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 14:50~15:00 [±¸¿¬¹ßÇ¥] Metastatic lymph node with ultrasonographic punctate echogenic foci (PEF) harbors PEF in primary thyroid cancer "¹Ú¼ö¸° (°Ç±¹´ëÇб³ ÀÇ°ú´ëÇÐ ÇÙÀÇÇаú)" ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 15:00~15:10 [±¸¿¬¹ßÇ¥] 10-year follow-up of radiofrequency ablation of benign thyroid nodule: perspective on technical outcome "½ÅÀçÈ£ (°í·Á´ëÇб³ ¾È¾Ïº´¿ø ¿µ»óÀÇÇаú)" ÈÞ½Ä 03¿ù 08ÀÏ 204,5È£ 15:20~15:40 Coffee Break () ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 15:40~16:20 Far advanced thyroid cancer - How far can we try? ÀåÇ×¼®(¿¬¼¼ÀÇ´ë ¿Ü°ú) ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 16:20~16:40 ÀÇÇÐ ¿¬±¸¿¡¼ÀÇ Generative AI¿Í Large Language Model: ÇöȲ°ú Àü¸Á Á¤±Ôȯ(¼º±Õ°ü´ëÇб³ »ï¼ºÀ¶ÇÕÀÇ°úÇпø) ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 16:40~17:00 °©»ó¼± ÀÇÇבּ¸¿¡¼ÀÇ Large Language ModelÀÇ Àû¿ë »ç·Ê ¹Ú±â¼º(Àü³²ÀÇ´ë ÇÙÀÇÇаú) ±³À°½Ã°£ 03¿ù 08ÀÏ 204,5È£ 17:00~17:20 Prompt Engineering: ÀÇÇÐ³í¹® ÀÛ¼º¿¡¼ÀÇ ChatGPT »ç¿ë Knowhow À̷οî(ÀÎÇÏÀÇ´ë ¿µ»óÀÇÇаú) Åä·Ð 03¿ù 08ÀÏ 204,5È£ 17:20~17:30 Discussion ()
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|